FLUTICASONE FUROATE TEVA 27,5 µg/spray Nasal spray suspension Fl/120spray

Each spray delivers 27,5 micrograms of fluticasone furoate.

Excipient with known effect : each spray delivers 8,25 micrograms of benzalkonium chloride.

For the full list of excipients, see section Composition.

FLUTICASONE FUROATE TEVA is indicated in adults, adolescents and children (from 6 years of age).

FLUTICASONE FUROATE TEVA is indicated for the treatment of the symptoms of allergic rhinitis.

Dosage

Adults and adolescents (from 12 years)

The recommended initial dose is two sprays (27,5 micrograms of fluticasone furoate per spray) in each nostril, once daily (total daily dose = 110 micrograms).

Once adequate control of symptoms is achieved, a reduction of the dose to one spray in each nostril (total daily dose = 55 micrograms) may be effective as maintenance treatment.

The dose should be adjusted to the minimum effective dose allowing maintenance of symptom control.

Children (aged 6 to 11 years)

The recommended initial dose is one spray (27,5 micrograms of fluticasone furoate per spray) in each nostril, once daily (total daily dose = 55 micrograms).

Children who do not respond completely to treatment with one spray in each nostril, once daily (total daily dose = 55 micrograms) may receive two sprays in each nostril, once daily (total daily dose = 110 micrograms).

Once adequate control of symptoms is achieved, it is recommended to reduce the dose to one spray in each nostril, once daily (total daily dose = 55 micrograms).

To obtain the optimal therapeutic effect, regular use is recommended. An effect appears from 8 hours after the first administration. However, several days of treatment may be necessary to obtain maximum efficacy, and the patient should be informed that their symptoms will improve with regular and continuous intake of the treatment (see section Pharmacodynamics). The duration of treatment should be limited to the period of allergen exposure.

Children aged less than 6 years

The safety and efficacy of FLUTICASONE FUROATE TEVA in children aged less than 6 years have not been established. The data currently available are described in sections Pharmacodynamics and Pharmacokinetics, but no dosage recommendation can be made.

Elderly patients

No dose adjustment is necessary in this population (see section Pharmacokinetics).

Renal impairment

No dose adjustment is necessary in this population (see section Pharmacokinetics).

Hepatic impairment

No dose adjustment is necessary in patients with hepatic impairment (see section Pharmacokinetics).

Method of administration

FLUTICASONE FUROATE TEVA, nasal spray suspension, is intended for nasal administration only.

The nasal spray should be shaken before use. The protective cap should then be removed. Before first use, the spray should be primed by pressing and releasing the pump at least 6 times (until a fine mist appears), holding the bottle upright.

Re-priming (approximately 6 sprays until a fine mist appears) is necessary if the cap has been removed for 5 days or if the spray has not been used for at least 30 days.

After each use, the spray must be cleaned and the cap replaced.

Hypersensitivity to the active substance or to any of the excipients listed in section Composition.

Systemic effects related to corticosteroids

Systemic effects associated with nasally administered corticosteroids may occur, particularly with high doses prescribed over prolonged periods. The risk of these effects is much lower than with orally administered corticosteroids, and these effects may vary between patients and between corticosteroid preparations used. Potential systemic effects may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and, more rarely, various psychological or behavioural effects, including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). Treatment with nasal corticosteroids at doses higher than those recommended may lead to adrenocortical suppression with clinical consequences. If doses higher than those recommended must be used, systemic corticosteroid supplementation should be considered during periods of stress or in case of surgical intervention.

No suppression of the hypothalamic-pituitary-adrenal (HPA) axis has been observed in adult, adolescent or paediatric subjects receiving fluticasone furoate at a dose of 110 micrograms once daily. However, the dose of nasally administered fluticasone furoate should always be reduced to the minimum dose that maintains effective control of rhinitis symptoms. As with all nasal corticosteroids, the total systemic exposure that may result from concomitant corticosteroid therapy by other routes of administration must be taken into account.

If impairment of adrenal function is suspected, caution is recommended when transferring a patient from systemic corticosteroid therapy to fluticasone furoate.

Visual disorders

Visual disturbances may be reported with systemic or local corticosteroid therapy. If a patient presents with symptoms such as blurred vision or other visual disturbances, they should be referred to an ophthalmologist to evaluate possible causes, including cataract, glaucoma, or rare conditions such as central serous chorioretinopathy (CSCR), which have been reported after systemic or local corticosteroid administration.

Growth retardation

Growth retardation has been reported in children receiving nasal corticosteroids at the recommended posology. Slowing of growth has been observed in children treated with fluticasone furoate at a dose of 110 micrograms per day for one year (see sections Adverse effects and Pharmacodynamics). The minimum effective dose to control symptoms should therefore be maintained in children (see section Dosage and administration). Regular monitoring of growth in children receiving long-term nasal corticosteroid therapy is therefore recommended. If growth retardation is observed, treatment should be reassessed in order to reduce, if possible, the nasal corticosteroid dose to the minimum dose that maintains symptom control. In addition, referral of the patient to a paediatric specialist should be considered (see section Pharmacodynamics).

Patients receiving ritonavir treatment

Concomitant administration of ritonavir is not recommended because of the risk of increased systemic exposure to fluticasone furoate (see section Interactions).

Excipients

This medicinal product contains benzalkonium chloride. Prolonged use may cause oedema of the nasal mucosa.

Interaction with CYP3A inhibitors

Fluticasone furoate is rapidly eliminated by a significant hepatic first-pass effect, mediated by cytochrome P450 3A4.

By analogy with results observed with another corticosteroid (fluticasone propionate), also metabolised by CYP3A4, concomitant administration of ritonavir is not recommended due to the risk of increased systemic exposure to fluticasone furoate.

Caution is recommended when concomitantly administering fluticasone furoate with potent CYP3A inhibitors (including cobicistat-containing medicinal products), as an increased risk of systemic undesirable effects is expected. Their co-administration should be avoided unless the expected benefit outweighs the increased risk of systemic corticosteroid undesirable effects; if this is the case, patients should be monitored for possible systemic corticosteroid-related undesirable effects. A drug interaction study of nasally administered fluticasone furoate with ketoconazole (a potent CYP3A4 inhibitor) showed that the number of subjects with measurable concentrations of fluticasone furoate was higher in the ketoconazole-treated group (6 subjects out of 20) than in the placebo group (1 subject out of 20). This slight increase in systemic exposure did not result in a statistically significant difference in cortisol levels at 24 hours between the two groups.

Enzyme induction and inhibition data suggest, in theory, no risk of metabolic interactions between fluticasone furoate and other compounds metabolised by cytochrome P450 at the clinically recommended nasal doses. Consequently, no clinical study has been conducted to investigate interactions between fluticasone furoate and other medicinal products.

Pregnancy

There are no reliable data on the use of fluticasone furoate in pregnant women. Studies performed in animals have shown that glucocorticoids induced malformations with cleft palate and intrauterine growth retardation. This is unlikely to be relevant for humans given the recommended nasal doses which result in minimal systemic exposure (see section Pharmacokinetics). Fluticasone furoate should only be used during pregnancy if the expected benefits for the mother outweigh the potential risks to the fetus or newborn.

Breast-feeding

The passage of fluticasone furoate into breast milk after nasal administration is not known.

Administration of fluticasone furoate to breastfeeding women should only be considered if the expected benefits for the mother outweigh the potential risks to the infant.

Fertility

There are no data on the effect of fluticasone furoate on fertility in humans.

FLUTICASONE FUROATE TEVA has no or negligible influence on the ability to drive and use machines.

Summary of the safety profile

The most frequently reported adverse reactions during treatment with fluticasone furoate are epistaxis, nasal ulceration and headache. The most serious adverse reactions reported are rare cases of hypersensitivity reactions, including anaphylaxis (fewer than 1 cases for 1 000 patients).

Table listing undesirable effects

More than 2 700 patients were treated with fluticasone furoate in the efficacy and safety studies in seasonal and perennial allergic rhinitis. The paediatric population exposed to fluticasone furoate in the efficacy and safety studies in seasonal and perennial allergic rhinitis included 243 patients aged 12 to < 18 years, 790 patients aged 6 to < 12 years and 241 patients aged 2 to < 6 years.

Data from large-scale clinical studies were used to determine the frequency of adverse reactions.

The following convention has been used to classify frequencies: Very common ≥ 1/10; Common ≥ 1/100 to < 1/10; Uncommon ≥ 1/1 000 to < 1/100; Rare ≥ 1/10 000 to < 1/1 000; Very rare < 1/10 000; frequency not known (cannot be estimated from the available data).

Description of selected adverse reactions

Epistaxis

* Epistaxis was generally of mild to moderate intensity. In adults and adolescents, the incidence of epistaxis was higher with long-term use (more than 6 weeks) compared with short-term use (up to 6 weeks).

Systemic effects

Administration of corticosteroids nasally, especially when prescribed at high doses for prolonged periods, may result in systemic effects (see section Warnings and precautions). Cases of growth retardation have been reported in children under nasal corticosteroid therapy.

** Cases of dyspnoea were reported in more than 1 % of patients in clinical trials with fluticasone furoate; similar rates were also observed in the placebo groups.

Paediatric population

Safety in children under 6 years of age has not been fully established. The frequency, type and severity of adverse reactions observed in the paediatric population are similar to those observed in the adult population.

Epistaxis

* In paediatric clinical studies lasting up to 12 weeks, the incidence of epistaxis was similar for patients treated with fluticasone furoate and placebo.

Growth retardation

*** In a one-year clinical study evaluating growth in prepubertal children receiving 110 micrograms of fluticasone furoate once daily, a mean difference in growth velocity of -0,27 cm per year was observed in the treatment group compared with placebo (see Clinical efficacy and safety).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr/.

In a bioavailability study, no systemic adverse effects were observed after administration, for three days, of intranasal doses up to 2 640 micrograms per day (see section Pharmacokinetics).

An acute overdose generally does not require any specific measures other than monitoring of the patient.

Pharmacotherapeutic classification: Nasal preparations, corticosteroids, ATC code: R01AD12.

Mechanism of action

Fluticasone furoate is a synthetic trifluorinated corticosteroid with a very high affinity for the glucocorticoid receptor and exerting potent anti-inflammatory activity.

Clinical efficacy and safety

Seasonal allergic rhinitis in adults and adolescents

Compared with placebo, fluticasone furoate nasal spray at a dose of 110 micrograms taken once daily significantly improved nasal symptoms (including rhinorrhoea, nasal congestion, sneezing and nasal pruritus) and ocular symptoms (including itching/burning, watery eyes/discharge and red eyes) in each of the 4 studies conducted. Efficacy was maintained for 24 hours following once-daily administration of the product.

A therapeutic effect appeared as early as 8 hours after the first administration, with further improvement during administration on the following days.

In each of the 4 studies conducted, the overall treatment response perceived by patients as well as their assessment on a quality of life scale (RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire) were significantly improved with fluticasone furoate nasal spray.

Perennial allergic rhinitis in adults and adolescents

In three studies, nasal symptoms and the overall treatment response perceived by patients were significantly improved with fluticasone furoate nasal spray at a dose of 110 micrograms taken once daily, compared with placebo.

In one study, ocular symptoms as well as quality of life (RQLQ) were significantly improved with fluticasone furoate nasal spray at a dose of 110 micrograms taken once daily, compared with placebo.

Efficacy was maintained for 24 hours following once-daily administration of the product.

In a two-year study evaluating the ocular tolerability of fluticasone furoate (110 micrograms once daily as intranasal spray), adults and adolescents with perennial allergic rhinitis received either fluticasone furoate (n = 367) or placebo (n = 181). The primary outcomes [time to onset of posterior subcapsular cataract (≥ 0,3 from baseline according to the Lens Opacities Classification System, version III (LOCS III grade)) and time to onset of an increase in intraocular pressure (IOP: ≥ 7 mmHg from baseline)] did not show statistically significant differences between the two groups. Increases in posterior subcapsular lens opacity (≥ 0,3 from baseline) were more frequently observed in subjects treated with 110 micrograms of fluticasone furoate [14 (4 %)] than in subjects receiving placebo [4 (2 %)]; these increases were transient for ten subjects in the fluticasone furoate group and for two subjects in the placebo group. Increases in IOP (≥ 7 mmHg from baseline) were more frequently observed in subjects treated with 110 micrograms of fluticasone furoate once daily: n = 7 (2 %) than in the placebo group: n = 1 (< 1 %). These events were transient for six subjects in the fluticasone furoate group and one subject in the placebo group. A posterior subcapsular lens opacity within ± 0,1 from baseline was observed for each eye in 95 % of subjects in both treatment groups at weeks 52 and 104, and an increase in posterior subcapsular lens opacity ≥ 0,3 from baseline was observed in ≤ 1 % of subjects in both treatment groups at week 104. IOP values within ± 5 mmHg from baseline were observed in the majority of subjects (> 95 %) at weeks 52 and 104. The increases in posterior subcapsular lens opacity or IOP were not accompanied by any adverse event of cataract or glaucoma type.

Paediatric population

Seasonal and perennial allergic rhinitis in children

Paediatric posology is based on the evaluation of efficacy data in children with allergic rhinitis.

In seasonal allergic rhinitis, fluticasone furoate nasal spray at a dose of 110 micrograms in one dose per day was shown to be effective; however, at a dose of 55 micrograms in one dose per day, no significant difference was observed between fluticasone furoate and placebo on all efficacy endpoints.

In perennial allergic rhinitis, fluticasone furoate nasal spray at a dose of 55 micrograms in one dose per day was shown to be more effective than fluticasone furoate at a dose of 110 micrograms in one dose per day over 4 weeks of treatment. An analysis post hoc analysis data collected at 6 and 12 weeks in this study, as well as a 6-week tolerability study on the HHS axis, showed the efficacy of fluticasone furoate nasal spray at a dose of 110 micrograms in one dose per day. In a 6-week study evaluating the effect of fluticasone furoate nasal spray at a dose of 110 micrograms in one dose per day on adrenal function in children aged 2 to 11 years, no significant effect on the 24-hour cortisol level was demonstrated compared with placebo.

A multicentre, randomised, double-blind, placebo-controlled, parallel-group study evaluated the effects of treatment with fluticasone furoate nasal spray at a dose of 110 micrograms once daily for one year on growth velocity measured by stadiometry, in 474 prepubertal children (aged 5 to 7,5 years for girls and 5 to 8,5 years for boys). Over a treatment period of 52 weeks, a lower mean growth velocity was observed in patients receiving fluticasone furoate (5,19 cm/year) compared with those receiving placebo (5,46 cm/year). The mean difference observed in the treatment group was -0,27 cm per year [95 % CI: -0,48 to -0,06].

Seasonal and perennial allergic rhinitis in children (under 6 years)

Tolerability and efficacy studies have been conducted in seasonal and perennial allergic rhinitis in a total of 271 patients aged 2 to 5 years, among whom 176 were exposed to fluticasone furoate. Tolerability and efficacy have not been clearly established in this group.

Absorption

Fluticasone furoate is partially absorbed through the gastrointestinal tract and undergoes an extensive first-pass hepatic and intestinal effect leading to negligible systemic exposure. An intranasal daily dose of 110 micrograms does not usually result in quantifiable plasma concentrations (< 10 pg/mL). The absolute bioavailability of fluticasone furoate administered nasally is 0,50 %, meaning that less than 1 microgram of fluticasone furoate would be available systemically after administration of 110 micrograms (see section Overdose).

Distribution

The binding of fluticasone furoate to plasma proteins is greater than 99 %. Fluticasone furoate is widely distributed with a steady-state volume of distribution that averages 608 L.

Biotransformation

Fluticasone furoate is rapidly cleared (total plasma clearance of 58,7 L/h) from the systemic circulation, mainly by hepatic metabolism, by the enzyme CYP3A4 of cytochrome P450, into an inactive 17ß-carboxylated metabolite (GW694301X). The main metabolic pathway is hydrolysis of the S-fluoromethyl carbothioate function to a 17ß-carboxylic acid metabolite. The studies in vivo have not shown cleavage of the furoate compound to form fluticasone.

Elimination

After oral and intravenous administration, elimination is mainly faecal, indicating excretion of fluticasone furoate and its metabolites via bile. After intravenous administration, the mean elimination half-life is 15,1 hours. Urinary excretion corresponds approximately to 1 and 2 % of the administered dose after oral and intravenous administration respectively.

Paediatric population

In most patients, fluticasone furoate is not quantifiable (< 10 pg/mL) after nasal administration of a daily dose of 110 micrograms. Measurable plasma concentrations were observed in 15,1 % of paediatric patients after nasal administration of a daily dose of 110 micrograms and in only 6,8 % of paediatric patients after administration of a daily dose of 55 micrograms. No increase in fluticasone furoate concentrations was found in the youngest children (aged less than 6 years). In subjects whose plasma levels were measurable after administration of 55 micrograms, median fluticasone furoate concentrations were 18,4 pg/mL and 18,9 pg/mL in children aged 2 to 5 years and 6 to 11 years, respectively.

At a dose of 110 micrograms, mean concentrations in subjects with quantifiable levels were 14,3 pg/mL and 14,4 pg/mL in children aged 2 to 5 years and 6 to 11 years, respectively. These values are similar to those observed in adults (over 12 years), for whom mean concentrations in subjects with measurable levels were 15,4 pg/mL and 21,8 pg/mL at doses of 55 micrograms and 110 micrograms, respectively.

Elderly

Pharmacokinetic data are available for only a small number of elderly patients (≥ 65 years, n = 23/872 ; 2,6 %). No increased incidence of elderly patients in whom plasma fluticasone furoate could be quantified was observed compared with younger patients.

Renal impairment

Fluticasone furoate was not detected in the urine of healthy volunteers after nasal administration. Less than 1 % of the administered dose is excreted in urine. Thus, renal impairment should not have an effect on the pharmacokinetics of fluticasone furoate.

Hepatic impairment

There are no data after nasal administration of fluticasone furoate in patients with hepatic impairment. The available data were obtained after inhaled administration of fluticasone furoate (as fluticasone furoate or the fluticasone furoate/vilanterol combination) in patients with hepatic impairment. These data can be extrapolated to nasal administration. In patients with moderate hepatic impairment (Child-Pugh class B), a study of oral inhalation of a single dose of 400 micrograms of fluticasone furoate showed an increase in Cmax (42 %) and in AUC(0-∞) (172 %) and a moderate decrease (23 % on average) in cortisol levels in these patients compared with healthy subjects. After repeated inhaled administration of fluticasone furoate/vilanterol for 7 days, systemic exposure to fluticasone furoate (measured by AUC(0–24)) was increased (on average by a factor of two) in subjects with moderate or severe hepatic impairment (Child-Pugh class B or C) compared with healthy subjects. The increase in systemic exposure to fluticasone furoate in subjects with moderate hepatic impairment (fluticasone furoate/vilanterol 200/25 micrograms) was associated with a reduction in cortisol levels of 34 % on average compared with healthy subjects. No effect on cortisol levels was observed in subjects with severe hepatic impairment (fluticasone furoate/vilanterol 100/12,5 micrograms). These observations suggest that the average exposure expected with a dose of 110 micrograms of nasal fluticasone furoate should not have an inhibitory effect on cortisol in this patient population.

The results of general toxicology studies were similar to those observed with other glucocorticoids and reflect an amplification of pharmacological effects. These observations do not appear relevant to humans, given the recommended nasal doses, which result in low systemic exposure. No genotoxic effect of fluticasone furoate was observed in conventional genotoxicity tests. Furthermore, no dose-dependent increase in the incidence of tumours was found in two-year inhalation studies in rats and mice.

2 years

Shelf life after first use: 2 months

Do not refrigerate. Do not freeze.

Always keep the cap on the spray pump.

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

• Indication(s) appearing in the marketing authorisation at the date of publication of this decree